{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=26",
    "query": {
      "intervention": "cyclophosphamide",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 2804,
    "total_pages": 281,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T18:37:20.537Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00002974",
      "title": "Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "hyperthermia treatment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "1996-07",
      "completion_date": "2003-04",
      "has_results": false,
      "last_update_posted_date": "2019-12-13",
      "last_synced_at": "2026-10-30T18:37:20.537Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002974"
    },
    {
      "nct_id": "NCT02623582",
      "title": "CD123 Redirected Autologous T Cells for AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2015-12",
      "completion_date": "2016-11-18",
      "has_results": false,
      "last_update_posted_date": "2017-10-17",
      "last_synced_at": "2026-10-30T18:37:20.537Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02623582"
    },
    {
      "nct_id": "NCT00134017",
      "title": "Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "6 Months to 65 Years"
      },
      "enrollment_count": 142,
      "start_date": "2004-06",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2018-08-31",
      "last_synced_at": "2026-10-30T18:37:20.537Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00134017"
    },
    {
      "nct_id": "NCT05000450",
      "title": "Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "ALLO-605",
          "type": "GENETIC"
        },
        {
          "name": "ALLO-647",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Allogene Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-06-06",
      "completion_date": "2023-10-11",
      "has_results": false,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-10-30T18:37:20.537Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Austin, Texas • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05000450"
    },
    {
      "nct_id": "NCT02529813",
      "title": "CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Biphenotypic Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Blasts 5 Percent or More of Bone Marrow Nucleated Cells",
        "CD19 Positive",
        "Minimal Residual Disease",
        "Non-Hodgkin Lymphoma",
        "Small Lymphocytic Lymphoma",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage IV Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Tisagenlecleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "1 Year to 80 Years"
      },
      "enrollment_count": 26,
      "start_date": "2015-12-16",
      "completion_date": "2021-11-08",
      "has_results": false,
      "last_update_posted_date": "2022-06-30",
      "last_synced_at": "2026-10-30T18:37:20.537Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02529813"
    },
    {
      "nct_id": "NCT00070018",
      "title": "S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Yttrium-90 ibritumomab tiuxetan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Indium-111 ibritumomab tiuxetan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2004-02",
      "completion_date": "2015-01-08",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-10-30T18:37:20.537Z",
      "location_count": 48,
      "location_summary": "Anchorage, Alaska • Burbank, California • Boise, Idaho + 33 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00070018"
    },
    {
      "nct_id": "NCT01705691",
      "title": "Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "HER2-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NSABP Foundation Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2012-09",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2021-10-06",
      "last_synced_at": "2026-10-30T18:37:20.537Z",
      "location_count": 18,
      "location_summary": "Denver, Colorado • Miami Beach, Florida • Albany, Georgia + 13 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Albany",
          "state": "Georgia"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01705691"
    },
    {
      "nct_id": "NCT02650635",
      "title": "TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Adenocarcinoma",
        "Metastatic Pancreatic Adenocarcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Melanoma of the Skin",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Solid Neoplasm",
        "Stage IV Breast Cancer",
        "Stage IV Non-Small Cell Lung Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Skin Melanoma",
        "Stage IVA Colorectal Cancer",
        "Stage IVA Pancreatic Cancer",
        "Stage IVB Colorectal Cancer",
        "Stage IVB Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "TLR8 Agonist VTX-2337",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2016-02-05",
      "completion_date": "2017-06-01",
      "has_results": false,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-10-30T18:37:20.537Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02650635"
    },
    {
      "nct_id": "NCT05578976",
      "title": "A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Epcoritamab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 900,
      "start_date": "2023-02-08",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-30T18:37:20.537Z",
      "location_count": 68,
      "location_summary": "Tucson, Arizona • Yuma, Arizona • Little Rock, Arkansas + 57 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05578976"
    },
    {
      "nct_id": "NCT02180867",
      "title": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alveolar Soft Part Sarcoma",
        "Angiomatoid Fibrous Histiocytoma",
        "Atypical Fibroxanthoma",
        "Clear Cell Sarcoma of Soft Tissue",
        "Epithelioid Malignant Peripheral Nerve Sheath Tumor",
        "Epithelioid Sarcoma",
        "Extraskeletal Myxoid Chondrosarcoma",
        "Extraskeletal Osteosarcoma",
        "Fibrohistiocytic Neoplasm",
        "Fibrosarcoma",
        "Inflammatory Myofibroblastic Tumor",
        "Intimal Sarcoma",
        "Leiomyosarcoma",
        "Liposarcoma",
        "Liver Embryonal Sarcoma",
        "Low Grade Fibromyxoid Sarcoma",
        "Low Grade Myofibroblastic Sarcoma",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Malignant Skin Granular Cell Tumor",
        "Malignant Triton Tumor",
        "Mesenchymal Chondrosarcoma",
        "Myxofibrosarcoma",
        "Myxoid Chondrosarcoma",
        "Myxoinflammatory Fibroblastic Sarcoma",
        "Nerve Sheath Neoplasm",
        "PEComa",
        "Pericytic Neoplasm",
        "Plexiform Fibrohistiocytic Tumor",
        "Sclerosing Epithelioid Fibrosarcoma",
        "Skin Glomus Tumor",
        "Stage IB Soft Tissue Sarcoma AJCC v7",
        "Stage IIB Soft Tissue Sarcoma AJCC v7",
        "Stage III Soft Tissue Sarcoma AJCC v7",
        "Stage IV Soft Tissue Sarcoma AJCC v7",
        "Synovial Sarcoma",
        "Undifferentiated High Grade Pleomorphic Sarcoma of Bone"
      ],
      "interventions": [
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2014-08-12",
      "completion_date": "2026-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-30T18:37:20.537Z",
      "location_count": 365,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02180867"
    }
  ]
}